MAY 26, 2020 1:39 PM PDT

Everyone Can Produce Antibodies Against COVID-19

WRITTEN BY: Annie Lennon

Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience symptoms, can develop antibodies capable of blocking the virus. Their findings offer hope for the success of a potential vaccine, and research avenues for more drugs to combat it. 

Since April 1st, a team of researchers including immunologists, medical scientists, and virologists, has been collecting blood samples from people who have recovered from COVID-19. In total, they collected samples from 149 people over five weeks. Each participant experienced symptoms for an average of 12 days and had their first symptoms an average of 39 days before donating their blood. 

To test their antibodies, The researchers mixed their blood with a pseudo-COVID-19 virus in lab conditions. They then measured how well the mixture was then able to infect human cells in a petri dish. 

Although most of the samples had a poor to modest antibody response, closer inspection revealed that the problem was more to do with how many antibodies were present- as opposed to whether they were effective. Moreover, the researchers noted that those whose blood had antibodies below detectable levels might have been able to resolve the infection so quickly that the antibodies were not needed to be produced. 

"This suggests just about everybody can do this, which is very good news for vaccines," says Michel C. Nussenzweig, head of the Laboratory of Molecular Immunology at Rockefeller, and lead author of the study. "It means if you were able to create a vaccine that elicits these particular antibodies, then the vaccine is likely to be effective and work for a lot of people."

The researchers were also able to identify three distinct antibodies with a high potency against the virus. They are thus working on developing these antibodies into drugs both to treat and prevent COVID-19. 

 

Sources: bioRxiv, Medical Xpress

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
AUG 15, 2022
Drug Discovery & Development
New Drug Candidate Treats Over 300 Drug Resistant Bacteria
AUG 15, 2022
New Drug Candidate Treats Over 300 Drug Resistant Bacteria
Researchers have identified a new molecule that shows promise in inhibiting over 300 drug-resistant bacteria, including ...
AUG 19, 2022
Neuroscience
Anterior Cingulate Cortex Plays a Key Role in Managing Additional Learning Tasks
AUG 19, 2022
Anterior Cingulate Cortex Plays a Key Role in Managing Additional Learning Tasks
A study published in Nature Communications reports that a key function of the anterior cingulate cortex (ACC) is to help ...
SEP 11, 2022
Microbiology
Using Yeast Cells to Make a Cancer Treatment
SEP 11, 2022
Using Yeast Cells to Make a Cancer Treatment
Vinblastine and vincristine are both common chemotherapies that are used to treat several types of cancer. The drugs sto ...
SEP 13, 2022
Cancer
Emerging Drug Targets in Cancer Immunotherapy
SEP 13, 2022
Emerging Drug Targets in Cancer Immunotherapy
Introduction Cancer is the second leading cause of death globally. According to estimates from the American Cancer Socie ...
SEP 15, 2022
Neuroscience
Food Insecurity Affects Brain Development
SEP 15, 2022
Food Insecurity Affects Brain Development
A recent study found that food insecurity affects brain development in mice. University of California Berkeley researche ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
Loading Comments...